Spectrum Pharma (SPPI) Easily Tops Q1 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
May 5, 2016 4:00 PM EDTSPI-2012 (eflapegrastim), a novel long-acting GCSF: A pivotal Phase 3 study was initiated and is currently enrolling patients with approximately 60 clinical sites open for enrollment in the U.S. Poziotinib, a novel pan-HER inhibitor: A Phase 2 trial was initiated and is enrolling breast cancer patients who have failed other HER2-directed therapies. Apaziquone for non-muscle invasive bladder cancer: FDA accepted NDA and assigned a PDFUA date of December 11, 2016. EVOMELA (melphalan) for injection: Company recently launched the drug and early indicators are positive.... More
